Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

AbbVie Profit Tops Analyst Estimates on Humira Sales

Humira sales rose 26 percent to $3.29 billion in the quarter, topping analysts’ expectations of $2.97 billion. Photographer: JB Reed/Bloomberg
Humira sales rose 26 percent to $3.29 billion in the quarter, topping analysts’ expectations of $2.97 billion. Photographer: JB Reed/Bloomberg

July 25 (Bloomberg) -- AbbVie Inc., the drugmaker buying Shire Plc to lower its tax rate, reported profit that beat analysts’ estimates on strong sales of the arthritis drug Humira.

Second-quarter net income rose 2.8 percent to $1.1 billion, or 68 cents a share, from $1.07 billion, or 66 cents, a year earlier, the company said in a statement today. Excluding one-time items, earnings were 82 cents a share, beating by 6 cents the average of 7 analysts’ estimates compiled by Bloomberg. Revenue gained 5 percent to $4.9 billion.

AbbVie, spun off from Abbott Laboratories last year, said on July 19 it would acquire Dublin-based Shire for $55 billion, adding drugs for attention deficit hyperactivity disorder and rare diseases to diversify its portfolio. AbbVie will also move its legal address abroad to lower its tax rate, making it the largest U.S. company to do a tax inversion deal.

The North Chicago, Illinois-based drugmaker currently relies on Humira, a rheumatoid arthritis injection for more than half of its revenue. Humira sales rose 26 percent to $3.29 billion in the quarter, topping analysts’ expectations of $2.97 billion.

AbbVie is also developing an experimental triple-pill regimen for hepatitis C as a competitor to Gilead Sciences Inc.’s drug Sovaldi, which reaped $3.5 billion in the second quarter. AbbVie expects to get approval from U.S. regulators later this year. Merck & Co. and Bristol-Myers Squibb Co. are also developing therapies for the viral disease.

Not including any potential revenue from the expected hepatitis C therapy, AbbVie confirmed its 2014 adjusted earnings forecast of $3.06 to $3.16 a share. The company also said third quarter earnings, excluding one-time items, would be 77 cents to 79 cents a share.

AbbVie shares declined 1.7 percent to $53.18 at the close in New York. The stock has gained 20 percent in the last 12 months.

To contact the reporter on this story: Caroline Chen in New York at cchen509@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Angela Zimm

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.